New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases Marketembed
Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH.
Market Reports Center One Stop Market Reaserch Shop Rising Stars Outlook 2016 - New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025! Browse Detail Report With TOC @ https://marketreportscenter.com/reports/139675/rising-stars-outlook-2016-new-emergence-ofpotential-tx-dx-options-could-transform-the-current-landscape-for-liver-diseases-nash Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year. Table Of Content 1. Conatus Pharmaceuticals (CNAT) Emricasan: Disease Modifying Potential across the Spectrum of Liver Diseases - KEY MILESTONES (CNAT) Market Reports Center One Stop Market Reaserch Shop - 2. Trends in overall population driven by significant improvement in MELD ?15 subgroup Figure 1 Conatus Pharma EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTH - Table 1 Conatus Pharma PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES - Table 2 Conatus Pharma COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH - Figure 2 Conatus Pharma EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES - Figure 3 Conatus Pharma EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES - Figure 4 Conatus Pharma EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS) Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/139675 - Figure 5 Conatus Pharma EMRICASAN: PHASE II DATA @ EASL, 2015 - Figure 6 Conatus Pharma EMRICASAN: PHASE II DATA @ AASLD, 2015 - Changes in Clinical, Biochemical, and Biomarker parameter from Baseline 2. Galectin Therapeutics (GALT) - Reversing Late-Stage NASH (Advanced Fibrosis) -KEY MILESTONES (GALT) - COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH -ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS - PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS) - GR-MD-02: PHI STUDY – SERUM BIOMARKERS EVALUATION - Figure 4 Galectin Therapeutics GR-MD-02: PRECLINICAL DATA – TX EFFECT ON NASH WITH FIBROSIS - Figure Galectin Therapeutics Market Reports Center One Stop Market Reaserch Shop PIPELINE PORTFOLIO 3. Galmed Pharmaceuticals (GLMD)-Aramchol: A Differentiated Approach, Targeting Early NASH and Potentially, NAFL Pts - KEY MILESTONES (GLMD) - Table 1 Galmed Pharmaceuticals COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH To Get Discount On The Report @ https://marketreportscenter.com/request-discount/139675 About Us: Market Reports Centeris an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable. Market Reports Center currently has more than 1,20,000 plus titles and 30+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies. Contact Information: Sam Collins Market Reports Center 1-646-883-3044 (US) [email protected] https://marketreportscenter.com http://marketreportscenter.blogspot.in/